BCI
URGN icon

Brinker Capital Investments’s UroGen Pharma URGN Stock Holding History

Brinker Capital Investments’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,008
Closed -$211K – 2254
2025
Q4 		$211K Sell
9,008
-2,000
-18% -$43.4K ﹤0.01% 2000
2025
Q3 		$220K Buy
+11,008
New +$198K ﹤0.01% 1926

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Brinker Capital Investments's URGN Position: Q1 2026 in Review

Brinker Capital Investments sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 9,008 shares — an estimated $211K sold.

Brinker Capital Investments first reported a position in URGN in Q3 2025 and held it in 2 quarters. The position peaked at $220K in Q3 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Brinker Capital Investments reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
  • Brinker Capital Investments sold 9,008 UroGen Pharma shares in Q1 2026, an estimated $211K.
  • Brinker Capital Investments first reported a position in UroGen Pharma in Q3 2025 and held it in 2 quarters.
  • Brinker Capital Investments's UroGen Pharma position peaked at $220K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.